CAMBRIDGE, U.K.—Biopharmaceutical company PhoreMost and medicinal chemistry company o2h discovery have linked up in a collaboration as of late June. Under the agreement, o2h will leverage its medicinal chemistry experience to advance PhoreMost’s pipeline through the hit-to-lead and lead-optimization stages. PhoreMost’s drug discovery programs are largely identified thanks to SITESEEKER, the company’s phenotypic screening platform, which helps PhoreMost in its quest to hit “undruggable” disease targets.

“We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs,” said Sunil Shah, CEO of o2h discovery. “Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK Biotech cluster for discovery and progressing the next generation of therapeutics.”